Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-B/IB system through the activation of AMP-activated protein kinase

International Journal of Molecular Medicine

Volumn 37, Issue 6, 2016, Pages 1558-1566

  Tang, Song Tao ^a,b,c   Su, Huan ^b   Zhang, Qiu ^c   Tang, Hai Qin ^b   Wang, Chang Jiang ^c   Zhou, Qing ^b   Wei, Wei ^a   Zhu, Hua Qing ^b   Wang, Yuan ^a,b  

^a Institute of Clinical Pharmacology   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c Departments of Endocrinology   (China)

Author keywords

Aortic endothelium; Diabetes; Endothelin 1; Sitagliptin

Indexed keywords

ENDOTHELIN 1; GLUCAGON LIKE PEPTIDE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; NITRIC OXIDE; SITAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; I KAPPA B KINASE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; AORTA FLOW; AORTA WALL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; RNA TRANSLATION; SIGNAL TRANSDUCTION; UPREGULATION; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; ARTERIOSCLEROSIS; BIOSYNTHESIS; CHEMICALLY INDUCED; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIPID DIET; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AORTA; ARTERIOSCLEROSIS; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; I-KAPPA B KINASE; MALE; NF-KAPPA B; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SITAGLIPTIN PHOSPHATE; STREPTOZOCIN;

EID: 84978878024     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2016.2578     Document Type: Article

References (32)

1. Wang J, Luben R, Khaw KT, Bingham S, Wareham NJ and Forouhi NG: Dietary energy density predicts the risk of clinically incident type 2 diabetes: the EPIC-Norfolk study. Diabetes Care 31: 2120-2125, 2008.
2. Wilmot EG, Edwardson CL, Achana FA, Davies MJ, Gorely T, Gray LJ, Khunti K, Yates T and Biddle SJ: Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. Diabetologia 55: 2895-2905, 2012.
3. Li J, Dong Y, Wu T and Tong N: Differences between western and Asian type 2 diabetes patients in the incidence of vascular complications and mortality: A systematic review of randomized controlled trials on lowering blood glucose. J Diabetes: Dec 11, 2015 (Epub ahead of print).
4. Sena CM, Pereira AM and Seiça R: Endothelial dysfunction-a major mediator of diabetic vascular disease. Biochim Biophys Acta 1832: 2216-2231, 2013.
5. Roberts AC and Porter KE: Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diab Vasc Dis Res 10: 472-482, 2013.
6. Drucker DJ: Glucagon-like peptides. Diabetes 47: 159-169, 1998.
7. Luft VC, Schmidt MI, Pankow JS, Hoogeveen RC, Couper D, Heiss G and Duncan BB; Atherosclerosis Risk in Communities Investigators: Dipeptidyl peptidase IV and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 33: 1109-1011, 2010.
8. Matheeussen V1, Waumans Y, Martinet W, Van Goethem S, Van der Veken P, Scharpé S, Augustyns K, De Meyer GR and De Meester I: Dipeptidyl peptidase in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis. Basic Res Cardiol 108: 350, 2013.
9. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ and Husain M: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 117: 2340-2350, 2008.
10. Nyström T1, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B and Sjöholm A: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287: E1209-E1215, 2004.
11. Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li RK, Volchuk A, Robinson LA, Billia F, Drucker DJ and Husain M: A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 127: 74-85, 2013.
12. Vittone F, Liberman A, Vasic D, Ostertag R, Esser M, Walcher D, Ludwig A, Marx N and Burgmaier M: Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. Diabetologia 55: 2267-2275, 2012.
13. Shah Z1, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, et al: Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124: 2338-2349, 2011.
14. Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K, Konishi M, et al: A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 59: 265-276, 2012.
15. Han L, Yu Y, Sun X and Wang B: Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways. Diabetes Res Clin Pract 97: 453-460, 2012.
16. Chen YX, Wang XQ, Fu Y, Yao YJ, Kong MY, Nie RQ and Wang JF: Pivotal role of infl ammation in vascular endothelial dysfunction of hyperlipidemic rabbit and effects by atorvastatin. Int J Cardiol 146: 140-144, 2011.
17. Drolet MC, Plante E, Battistini B, Couet J and Arsenault M: Early endothelial dysfunction in cholesterol-fed rabbits: a non-invasive in vivo ultrasound study. Cardiovasc Ultrasound 2: 10, 2004.
18. Tang ST, Su H, Zhang Q, Tang HQ, Wang CJ, Zhou Q, Wei W, Zhu HQ and Wang Y: Melatonin attenuates aortic endothelial permeability and arteriosclerosis in streptozotocin-induced diabetic rats: possible role of MLCK-and MLCP-dependent MLC phosphorylation. J Cardiovasc Pharmacol Ther 21: 82-92, 2016.
19. Zhou B1, Pan Y, Hu Z, Wang X, Han J, Zhou Q, Zhai Z and Wang Y: All-trans-retinoic acid ameliorated high fat diet-induced atherosclerosis in rabbits by inhibiting platelet activation and inflammation. J Biomed Biotechnol 2012: 259693, 2012.
20. Picatoste B1, Ramírez E, Caro-Vadillo A, Iborra C, Ares Carrasco S, Egido J, Tuñón J and Lorenzo O: Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS One 8: e78330, 2013.
21. Zhao HJ, Xu Q, Zhang GY, Liu Y, Yu T, Li HY, Yang LN, Wang HY and Xie LB: Therapeutic effects of GLP-1 analog on rats with experimental diabetes mellitus. J Jilin University 33: 474-479, 2007.
22. Pasterkamp G: Methods of accelerated atherosclerosis in diabetic patients. Heart 99: 743-749, 2013.
23. Böhm F and Pernow J: The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 76: 8-18, 2007.
24. Cicek FA, Kandilci HB and Turan B: Role of ROCK upregulation in endothelial and smooth muscle vascular functions in diabetic rat aorta. Cardiovasc Diabetol 12: 51, 2013.
25. Piechota A and Goraca A: Influence of nuclear factor-B inhibition on endothelin-1 induced lung edema and oxidative stress in rats. J Physiol Pharmacol 62: 183-188, 2011.
26. Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M, Hong M, Stier G, Sattler M, Schleicher E, Speiser W and Nawroth PP: Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 49: 1561-1570, 2000.
27. Ho FM, Lin WW, Chen BC, Chao CM, Yang CR, Lin LY, Lai CC, Liu SH and Liau CS: High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt eNOS pathway. Cell Signal 18: 391-399, 2006.
28. Suzuki J, Ogawa M, Muto S, Itai A, Isobe M, Hirata Y and Nagai R: Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases. Expert Opin Investig Drugs 20: 395-405, 2011.
29. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R and Watada H: Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59: 1030-1037, 2010.
30. Hattori Y, Jojima T, Tomizawa A, Satoh H, Hattori S, Kasai K and Hayashi T: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 53: 2256-2563, 2010.
31. Zeng Y, Li C, Guan M, Zheng Z, Li J, Xu W, Wang L, He F and Xue Y: The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK and MAPK-dependent mechanisms. Cardiovasc Diabetol 13: 32, 2014.
32. Dai Y, Mehta JL and Chen M: Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc Drugs Ther 27: 371-380, 2013.